Skyline Diagnostics | GenomeWeb

Skyline Diagnostics

The consortium aims to profile up to 800 multiple myeloma patient samples using the Affymetrix platform with a goal of developing a list of predictive biomarkers.

The genetic test determines risk levels and prognosis for patients with multiple myeloma based on the SKY92 gene signature.

Dutch molecular diagnostics company SkylineDx recently established a presence in Boston to bolster its outreach to the North American market.

SkylineDx has acquired all assets from recently shuttered Skyline Diagnostics and will continue to develop and commercialize the latter's menu of microarray-based tests, BioArray News has learned.

Kurt Schmidt has been appointed CEO of Skyline Diagnostics. Schmidt joins Skyline from Agendia, where he had served as chief financial officer since 2009.

This story was originally posted on June 22.

Skyline will collaborate with Janssen to develop a test to identify patients at increased risk of side effects from a multiple myeloma drug.

Skyline will use its expertise and technologies in genetic profiling and bioinformatics to generate and analyze diagnostics information related to an undisclosed compound from Janssen.


A startup wants to match customers to wine based on their DNA and one critic calls the idea 'silly,' Stat News reports.

Researchers trace the origins of brown rats using genetic analysis to China, the New York Times reports.

In Science this week: gene flow between ancient chimpanzees and bonobos, and more.

In Nature this week: genetic history of HIV in the US, and more.